Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT02207530 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: MEDI4736

Sponsor

AstraZeneca

Collaborators

[object Object]